Quince Therapeutics, Inc.
QNCX
$30.32
$0.822.76%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -310.20% | 191.01% | -193.54% | 16.24% | -6.78% |
| Total Depreciation and Amortization | 13.89% | -7.69% | 8.33% | 2.86% | 9.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 255.71% | -350.15% | 401.46% | -49.25% | 93.40% |
| Change in Net Operating Assets | -218.70% | -119.09% | 6,327.84% | 110.36% | -191.27% |
| Cash from Operations | -147.63% | 27.23% | -5.57% | 13.03% | -18.89% |
| Capital Expenditure | -- | -- | 94.59% | 41.27% | 14.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | 48.61% | 573.05% | -127.69% | -44.19% |
| Cash from Investing | -33.33% | 48.68% | 553.17% | -129.49% | -44.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -64.30% | 636.87% | 47.82% | -90.45% | 16,465.52% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,053.58% | 364.26% | 47.82% | -90.45% | 16,465.52% |
| Foreign Exchange rate Adjustments | 84.34% | -447.57% | -551.22% | -315.79% | -89.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 691.79% | 2,021.31% | 93.80% | -214.57% | 480.82% |